About DCprime
DCprime is a Healthcare company based in Leiden (Netherlands) founded in 2005, and was acquired by Immunicum in November 2020. Novel cancer immunotherapies are developed using the DCOne platform. DCprime offers products and services including Relapse Vaccines and Cancer Immunotherapy. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Immunicum AB.
Company details
DCPrime was established in 2005 in Leiden, Netherlands, within the biotechnology sector. Focus is placed on clinical-stage cancer immunotherapies derived from the DCOne platform, which integrates antigen carrier functions with dendritic cell immune stimulation. The lead product, DCP-001, is evaluated in phase II trials for Acute Myeloid Leukemia patients post-chemotherapy response. Further applications are investigated for hematological malignancies, multiple myeloma, ovarian cancer, and additional indications.
- Headquarters Leiden, Netherlands
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website dcprime.com
- Social LinkedIn X
- Acquired by Immunicum (Nov 2020)
- Legal Name Immunicum Ab
- Latest Funding Round$6.49M (USD), Grant
Jan 2016
- InvestorsEuropean Commission
& 6 more
- Acquired byImmunicum
(Nov 2020)
Products & Services of DCprime
DCprime offers a comprehensive portfolio of products and services, including Relapse Vaccines and Cancer Immunotherapy.
Vaccines aimed at preventing cancer relapse in patients.
Therapies using dendritic cells for cancer treatment.
Funding Insights of DCprime
- Total Rounds 6
- Last Round Grant — $6.49M
- Investors Count 6
All 6 funding rounds of DCprime with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $6.49M | Grant | – | – | |
| Jan 2016 | $537,733 | Grant | – | – | |
| Jun 2015 | Grant | – | – | ||
| Oct 2014 | Series A | – | SkylineDX, Van Herk Groep | – | |
| Jan 2013 | Grant | – | – | ||
| Sep 2010 | Seed | – | – |
7 investors in total: 7 institutional.
Investors in DCprime
DCprime has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include European Commission, SkylineDX and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life-Sciences & Offline focused VC firm funding companies in Netherlands | vanherkgroep.nl | Rotterdam, Netherlands | ||
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US | thujacapital.com | Utrecht, Netherlands | ||
Institution of the European Union responsible for upholding the EU treaties | 1958 | ec.europa.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
| eurostars-eureka.eu | ||||
Gene expression profiling tests are provided for personalized medicine. | 2005 | skylinedx.com | Rotterdam, Netherlands | |
Allogeneic dendritic cells based vaccines, T-cell therapy for the treatment of cancer | 2002 | immunicum.se | Gothenburg, Sweden |
Investor details for DCprime
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of DCprime
4 dated milestones of DCprime across 15 years, from founding to its latest funding, stage changes and deals.
- Founded DCprime is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $6.5M.
- Exit Acquired by Immunicum.
Web traffic of DCprime
The website of DCprime (dcprime.com) receives about 4K visits a month.
- Monthly visits4K
▲ 350.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dcprime
Complete news archive for DCprime
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DCprime
DCprime was founded in 2005 and raised its 1st funding round 5 years after it was founded.
DCprime is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
DCPrime was established in 2005 in Leiden, Netherlands, within the biotechnology sector. Focus is placed on clinical-stage cancer immunotherapies derived from the DCOne platform, which integrates antigen carrier functions with dendritic cell immune stimulation. The lead product, DCP-001, is evaluated in phase II trials for Acute Myeloid Leukemia patients post-chemotherapy response. Further applications are investigated for hematological malignancies, multiple myeloma, ovarian cancer, and additional indications.
DCprime offers Relapse Vaccines and Cancer Immunotherapy.
DCprime has 7 investors. Key investors include European Commission, SkylineDX, European Union, Immunicum, and Eurostars.
DCprime operates through Immunicum Ab.
Yes. DCprime was acquired by Immunicum in November 2020.